Abstract: Autonomous aerial navigation in low-light and no-light conditions includes using night mode obstacle avoidance intelligence, training, and mechanisms for vision-based unmanned aerial vehicle (UAV) navigation to enable autonomous flight operations of a UAV in low-light and no-light environments using infrared data.

Abstract: The DPT INSTRUCTOR provides unprecedented exercise instruction guidance by applying unparalleled precision and pinpoint accuracy that comes from combining professional exercise instructor expertise, physics and computer electronics. Considering the marketability of renowned professional/celebrity instructors who have their own unique style, technique, format and dedicated customers. The DPT INSTRUCTOR provides exclusive programming and formulation to guide and exact the expert training regiment of any fitness instructors individual form, execution, posture, expertise and technique.

Abstract: A game navigation interface for electronic content is described. A computer-implement system may comprise a content delivery platform operative to manage multimedia content. The computer-implemented system may further comprise a game navigation application operative to manage a game for the content delivery platform. The game navigation application may comprise a monitoring component operative to monitor navigation commands for navigating multimedia content provided by the content delivery platform, and output a game trigger signal based on the navigation commands. The game navigation application may further comprise a game navigation component operative to receive the game trigger signal, and select a game arranged to assist a user in navigating the multimedia content in response to the game trigger signal. Other embodiments are described and claimed.

Abstract: The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel steroselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient.

Abstract: The DPT INSTRUCTOR provides unprecedented exercise instruction guidance by applying unparalleled precision and pinpoint accuracy that comes from combining professional exercise instructor expertise, physics and computer electronics. Considering the marketability of renowned professional/celebrity instructors who have their own unique style, technique, format and dedicated customers. The DPT INSTRUCTOR provides exclusive programming and formulation to guide and exact the expert training regiment of any fitness instructors individual form, execution, posture, expertise and technique.

Abstract: Techniques to provide a topic-based social environment are disclosed. A topic-based social environment may generate a user account and a user profile. The topic-based social environment may allow a user to follow other users, discussions, content, and specific activities of interest. The environment may retrieve contributions of followed entities according to the user's profile and display the contributions in one user interface. The environment may generate a feed from the retrieved contributions to display to a user. The environment may allow a user to build a profile that is specific to the topic of the community. Other embodiments are described and claimed.

Abstract: The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel stereoselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient.

Abstract: A game navigation interface for electronic content is described. A computer-implement system may comprise a content delivery platform operative to manage multimedia content. The computer-implemented system may further comprise a game navigation application operative to manage a game for the content delivery platform. The game navigation application may comprise a monitoring component operative to monitor navigation commands for navigating multimedia content provided by the content delivery platform, and output a game trigger signal based on the navigation commands. The game navigation application may further comprise a game navigation component operative to receive the game trigger signal, and select a game arranged to assist a user in navigating the multimedia content in response to the game trigger signal. Other embodiments are described and claimed.

Abstract: The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel stereoselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient.

Abstract: The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel steroselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient.

Abstract: The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel steroselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient.

Abstract: The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel steroselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient.

Abstract: The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel steroselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient.

Abstract: Disclosed is a method and apparatus for processing baled tobacco leaves to separate the lamina portions of the leaves from the stem portions. The bale is cut symmetrically, crosswise to its length, into three or preferably five separate sections, of different characteristic types. A center section is cut from the middle of the bale. On each side of the center section a second section is cut; and two end sections are preferably cut, one at each end of the bale. The different types of sections have different lamina-to-stem ratios, and are processed differently. The second sections are coarsely threshed, to dislodge the larger lamina portions of the leaves from the stem portions therein, and the coarsely threshed material is separated into a first light fraction (comprising mostly lamina) and a first heavy fraction (enriched in stem content). The center section can be combined with the light fraction and can be dried and packed without the necessity of further threshing.